1 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
2 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
3 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
4 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
5 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
6 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
7 |
ADORA1
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
8 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D00045
D00045
|
Adenosine
| 3件: 13 13, 58, 65 |
9 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D02769
D02769
|
Adenosine phosphate
| 1件: 46 46 |
10 |
ADORA3
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10971
D10971
|
Piclidenoson
| 1件: 46 46 |
11 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
12 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
13 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
14 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
15 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
16 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
17 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
18 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
19 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
20 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
21 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
22 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
23 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
24 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
25 |
ADRA1D
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
26 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
27 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
28 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
29 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
30 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
31 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
32 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
33 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
34 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
35 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
36 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
37 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
38 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
39 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
40 |
ADRA1B
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
41 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
42 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
43 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
44 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
45 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D00454
D00454
|
Olanzapine
| 2件: 2 2, 8 |
46 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
47 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D01965
D01965
|
Silodosin
| 2件: 6 6, 13 |
48 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
49 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
50 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D07124
D07124
|
Alfuzosin
| 1件: 13 13 |
51 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
52 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
53 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08220
D08220
|
Midodrine
| 3件: 6 6, 17, 58 |
54 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08365
D08365
|
Phenylephrine
| 1件: 22 22 |
55 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
56 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08560
D08560
|
Tamsulosin
| 1件: 13 13 |
57 |
ADRA1A
| 4件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion | D08569
D08569
|
Terazosin
| 1件: 6 6 |
58 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
59 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
60 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
61 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
62 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
63 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
64 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
65 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00560
D00560
|
Pimozide
| 1件: 2 2 |
66 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
67 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
68 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
69 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
70 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
71 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08031
D08031
|
Guanfacine
| 1件: 193 193 |
72 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
73 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
74 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
75 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
76 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
77 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
78 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
79 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
80 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
81 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
82 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
83 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
84 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
85 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
86 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
87 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
88 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
89 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
90 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
91 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
92 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
93 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
94 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
95 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
96 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
97 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00270
D00270
|
Chlorpromazine
| 1件: 254 254 |
98 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00281
D00281
|
Clonidine
| 4件: 6 6, 65, 70, 78 |
99 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00283
D00283
|
Clozapine
| 1件: 6 6 |
100 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00514
D00514
|
Dexmedetomidine
| 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 |
101 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
102 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
103 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D04375
D04375
|
Guanabenz
| 2件: 2 2, 13 |
104 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07461
D07461
|
Apraclonidine
| 1件: 11 11 |
105 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D07540
D07540
|
Brimonidine
| 2件: 13 13, 90 |
106 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08207
D08207
|
Methylergometrine
| 1件: 280 280 |
107 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
108 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08482
D08482
|
Rilmenidine
| 1件: 8 8 |
109 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08611
D08611
|
Tizanidine
| 1件: 13 13 |
110 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D08685
D08685
|
Yohimbine
| 1件: 6 6 |
111 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
112 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
113 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
114 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00235
D00235
|
Atenolol
| 1件: 167 167 |
115 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
116 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
117 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00432
D00432
|
Nadolol
| 1件: 6 6 |
118 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
119 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02342
D02342
|
Bisoprolol
| 4件: 58 58, 67, 86, 113 |
120 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
121 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02358
D02358
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
122 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
123 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03879
D03879
|
Dobutamine
| 4件: 57 57, 58, 86, 215 |
124 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05127
D05127
|
Nebivolol
| 4件: 17 17, 85, 113, 167 |
125 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07660
D07660
|
Celiprolol
| 1件: 168 168 |
126 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07916
D07916
|
Esmolol
| 1件: 58 58 |
127 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
128 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
129 |
ADRB1
| 8件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
130 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
131 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
132 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
133 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
134 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
135 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00432
D00432
|
Nadolol
| 1件: 6 6 |
136 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
137 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| 12件: 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 |
138 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02151
D02151
|
Tulobuterol
| 1件: 6 6 |
139 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
140 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05792
D05792
|
Salmeterol
| 1件: 299 299 |
141 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07713
D07713
|
Clenbuterol
| 5件: 1 1, 2, 6, 13, 256 |
142 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07990
D07990
|
Formoterol
| 3件: 85 85, 228, 299 |
143 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08092
D08092
|
Isoxsuprine
| 1件: 13 13 |
144 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08124
D08124
|
Levosalbutamol
| 1件: 49 49 |
145 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
146 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
147 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08570
D08570
|
Terbutaline
| 1件: 118 118 |
148 |
ADRB2
| 6件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
149 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
150 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
151 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
152 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
153 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
154 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
155 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
156 |
ADRB3
| 7件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D09535
D09535
|
Mirabegron
| 4件: 6 6, 13, 53, 226 |
157 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00150
D00150
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
158 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00400
D00400
|
Valsartan
| 7件: 57 57, 58, 66, 75, 218, 222, 224 |
159 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00522
D00522
|
Candesartan
| 2件: 58 58, 67 |
160 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00523
D00523
|
Irbesartan
| 4件: 66 66, 167, 168, 222 |
161 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00626
D00626
|
Candesartan cilexetil
| 1件: 67 67 |
162 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00627
D00627
|
Telmisartan
| 2件: 66 66, 67 |
163 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D02014
D02014
|
Angiotensin II
| 7件: 17 17, 19, 46, 66, 86, 222, 224 |
164 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D08146
D08146
|
Losartan
| 17件: 17 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
165 |
AGTR1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Cortisol synthesis and secretion, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D11776
D11776
|
Sparsentan
| 3件: 66 66, 218, 222 |
166 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D01227
D01227
|
Bosentan
| 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
167 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07077
D07077
|
Ambrisentan
| 7件: 51 51, 84, 85, 86, 88, 210, 211 |
168 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07171
D07171
|
Sitaxentan
| 1件: 86 86 |
169 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07538
D07538
|
Bosentan
| 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
170 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07741
D07741
|
Zibotentan
| 1件: 51 51 |
171 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D10135
D10135
|
Macitentan
| 5件: 51 51, 85, 86, 88, 210 |
172 |
EDNRA
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D11776
D11776
|
Sparsentan
| 3件: 66 66, 218, 222 |
173 |
EDNRB
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D01227
D01227
|
Bosentan
| 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
174 |
EDNRB
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D07538
D07538
|
Bosentan
| 10件: 41 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
175 |
EDNRB
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D10135
D10135
|
Macitentan
| 5件: 51 51, 85, 86, 88, 210 |
176 |
GUCY1A2
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D00517
D00517
|
Amyl Nitrite
| 1件: 58 58 |
177 |
GUCY1A2
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| 6件: 51 51, 84, 86, 88, 225, 299 |
178 |
GUCY1A1
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D00517
D00517
|
Amyl Nitrite
| 1件: 58 58 |
179 |
GUCY1A1
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| 6件: 51 51, 84, 86, 88, 225, 299 |
180 |
GUCY1B1
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D00517
D00517
|
Amyl Nitrite
| 1件: 58 58 |
181 |
GUCY1B1
| 11件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| 6件: 51 51, 84, 86, 88, 225, 299 |
182 |
INSR
| 18件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy | D03230
D03230
|
Insulin human
| 2件: 96 96, 156 |
183 |
INSR
| 18件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy | D03250
D03250
|
Insulin glargine
| 1件: 299 299 |
184 |
INSR
| 18件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Diabetic cardiomyopathy | D04539
D04539
|
Insulin detemir
| 1件: 299 299 |
185 |
KCNJ8
| 1件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
186 |
MYH7
| 5件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Thyroid hormone signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D12265
D12265
|
Mavacamten
| 1件: 58 58 |
187 |
ATP1A1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
188 |
ATP1A1
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
189 |
ATP1A2
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
190 |
ATP1A2
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
191 |
ATP1A3
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
192 |
ATP1A3
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
193 |
ATP1A4
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00297
D00297
|
Digitoxin
| 1件: 299 299 |
194 |
ATP1A4
| 11件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Mineral absorption | D00298
D00298
|
Digoxin
| 3件: 8 8, 46, 210 |
195 |
NPR1
| 8件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion | D04051
D04051
|
Erythrityl tetranitrate
| 1件: 46 46 |
196 |
NPR1
| 8件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion | D05147
D05147
|
Nesiritide
| 2件: 46 46, 58 |
197 |
NPR2
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway | D04051
D04051
|
Erythrityl tetranitrate
| 1件: 46 46 |
198 |
NPR2
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway | D11190
D11190
|
Vosoritide
| 1件: 276 276 |
199 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05111
D05111
|
Nalmefene
| 1件: 6 6 |
200 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
201 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| 5件: 6 6, 13, 70, 226, 298 |
202 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| 2件: 13 13, 97 |
203 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08246
D08246
|
Nalbuphine
| 1件: 85 85 |
204 |
OPRD1
| 3件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08249
D08249
|
Naloxone
| 2件: 6 6, 226 |
205 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
206 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
207 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D00528
D00528
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
208 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D01453
D01453
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
209 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
210 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D07546
D07546
|
Bucladesine
| 1件: 246 246 |
211 |
PDE2A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Morphine addiction | D07961
D07961
|
Flavoxate
| 1件: 226 226 |
212 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
213 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
214 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D00417
D00417
|
Milrinone
| 1件: 294 294 |
215 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
216 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
217 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
218 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D01896
D01896
|
Cilostazol
| 3件: 46 46, 51, 70 |
219 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D04720
D04720
|
Levosimendan
| 1件: 2 2 |
220 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
221 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D07546
D07546
|
Bucladesine
| 1件: 246 246 |
222 |
PDE3A
| 5件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Renin secretion, Morphine addiction | D07961
D07961
|
Flavoxate
| 1件: 226 226 |
223 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00227
D00227
|
Aminophylline
| 1件: 63 63 |
224 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00371
D00371
|
Theophylline
| 2件: 236 236, 299 |
225 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00417
D00417
|
Milrinone
| 1件: 294 294 |
226 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
227 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01385
D01385
|
Ibudilast
| 2件: 2 2, 13 |
228 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
229 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01896
D01896
|
Cilostazol
| 3件: 46 46, 51, 70 |
230 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D04720
D04720
|
Levosimendan
| 1件: 2 2 |
231 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D06103
D06103
|
Theophylline
| 2件: 236 236, 299 |
232 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D07546
D07546
|
Bucladesine
| 1件: 246 246 |
233 |
PDE3B
| 9件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D07961
D07961
|
Flavoxate
| 1件: 226 226 |
234 |
PPP3CA
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
235 |
PPP3CA
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
236 |
PPP3CA
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
237 |
PPP3CA
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
238 |
PPP3CA
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
239 |
PPP3CB
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
240 |
PPP3CB
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
241 |
PPP3CB
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
242 |
PPP3CB
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
243 |
PPP3CB
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
244 |
PPP3CC
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
245 |
PPP3CC
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
246 |
PPP3CC
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
247 |
PPP3CC
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
248 |
PPP3CC
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
249 |
PPP3R1
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
250 |
PPP3R1
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
251 |
PPP3R1
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
252 |
PPP3R1
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
253 |
PPP3R1
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
254 |
PPP3R2
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
255 |
PPP3R2
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
256 |
PPP3R2
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
257 |
PPP3R2
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
258 |
PPP3R2
| 24件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
259 |
PRKCE
| 10件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Tight junction, Fc gamma R-mediated phagocytosis, Inflammatory mediator regulation of TRP channels, Type II diabetes mellitus, Insulin resistance, Shigellosis, MicroRNAs in cancer | D09671
D09671
|
Sotrastaurin
| 1件: 97 97 |
260 |
MAP2K1
| 77件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
261 |
MAP2K1
| 77件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
262 |
MAP2K1
| 77件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
263 |
MAP2K1
| 77件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
264 |
MAP2K1
| 77件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
265 |
MAP2K2
| 66件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
266 |
MAP2K2
| 66件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
267 |
MAP2K2
| 66件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
268 |
MAP2K2
| 66件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
269 |
MAP2K2
| 66件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
270 |
RAF1
| 69件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
271 |
ROCK1
| 18件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer | D07941
D07941
|
Fasudil
| 4件: 2 2, 5, 7, 51 |
272 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
273 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
274 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
275 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
276 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
277 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
278 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
279 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
280 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
281 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
282 |
CACNA1C
| 26件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
283 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
284 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
285 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
286 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
287 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
288 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
289 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
290 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
291 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
292 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
293 |
CACNA1D
| 25件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
294 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
295 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
296 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
297 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
298 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
299 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
300 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
301 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
302 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
303 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
304 |
CACNA1F
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
305 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
306 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
307 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
308 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
309 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
310 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
311 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
312 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
313 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
314 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
315 |
CACNA1S
| 20件: MAPK signaling pathway MAPK signaling pathway, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
316 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00302
D00302
|
Dipyridamole
| 6件: 46 46, 49, 51, 66, 96, 224 |
317 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00528
D00528
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
318 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D01453
D01453
|
Caffeine
| 8件: 2 2, 6, 21, 46, 78, 96, 97, 265 |
319 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02008
D02008
|
Tadalafil
| 7件: 6 6, 51, 75, 84, 86, 113, 210 |
320 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08514
D08514
|
Sildenafil
| 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
321 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08668
D08668
|
Vardenafil
| 3件: 13 13, 86, 299 |
322 |
PDE5A
| 3件: Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D10027
D10027
|
Udenafil
| 2件: 86 86, 210 |
323 |
ROCK2
| 19件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D07941
D07941
|
Fasudil
| 4件: 2 2, 5, 7, 51 |
324 |
ROCK2
| 19件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D11815
D11815
|
Belumosudil
| 2件: 51 51, 85 |